Despite disruptions to in-person selling and recruitment during the COVID-19 pandemic, USANA has experienced sales gains, according to the company’s recent earnings call. USANA reported $259 million for the second quarter 2020, compared to $256 million for the same quarter the prior year. The company brought in $1.32 in earnings per diluted share, or 13 cents more than expected. USANA projects sales of $1.05 billion to $1.10 billion for full year 2020. Its previous forecast had a range of $1 billion to $1.08 billion. CFO Doug Hekking said that results had been sustained due to demand for its immunity support products. A return to “somewhat normal in mainland China” has also benefited the company, according to CEO Kevin Guest.